Trexquant Investment 13F: Adds $2.1M to ARWR Stake

Trexquant Expands Its Biotech Holdings

Trexquant Investment increased its holdings in Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR) by 10.4% during the period ended May 15, 2026, according to a recent Form 13F filing with the SEC. Because 13F filings look backward at past quarters, this report captures a snapshot in time and might not reflect the fund's current holdings today.

Details of the Trade

The fund added 26,170 shares to its portfolio during the period, growing its prior stake of 250,944 shares up to a total of 277,114 shares. Based on market prices around the filing, that total position was valued at about $22.59 million. Trexquant's quantitative strategy often involves balancing large baskets of equities, making adjustments based on proprietary trading models.

Stock Price and Valuation Context

Arrowhead Pharmaceuticals shares traded near $81.51. The stock sits between its 52-week low of $31.45 and its 52-week high of $95.49, holding above its 200-day moving average of $72.54. The company carries a market capitalization of $9.72 billion and has a forward P/E of -14.31, reflecting a lack of current profitability as it invests heavily in clinical trials.

Recent Earnings Performance

For its most recent reporting period, Arrowhead posted $669.49 million in revenue with a revenue growth rate of 1.71%. The firm reported a net margin of -0.4779 and a return on equity of -0.55207, alongside an earnings per share of -$2.28. The company's next earnings report is expected on November 24, 2026.

Analysts Set New Price Targets

Wall Street firms maintain an upbeat view on the stock with a consensus recommendation of strong buy and 12 analyst opinions on record. On October 15, 2026, Chardan Capital maintained its Buy rating with a $115.00 price target. On the same day, HC Wainwright & Co. reiterated its Buy rating with a $120.00 price target. Earlier, Citigroup initiated coverage with a Buy rating and a $108.00 target on September 8, 2026.

Inside Arrowhead Pharmaceuticals

Headquartered in Pasadena, California, Arrowhead Pharmaceuticals develops medicines for intractable diseases using RNA interference technologies. Its clinical pipeline features candidates like plozasiran and zodasiran in late-stage Phase 3 studies, alongside several early-stage programs targeting cardiometabolic and genetic disorders. The company relies on key licensing agreements with major pharmaceutical partners to advance its therapeutic pipeline.

What's Ahead for Arrowhead Pharmaceuticals, Inc.

Investors tracking Trexquant's portfolio will look toward upcoming SEC filings to see if the quantitative fund continues adding to its healthcare positions. The broader trajectory for Arrowhead will depend on clinical trial milestones and upcoming earnings announcements later in the year.